본문으로 건너뛰기
← 뒤로

ESTRO-ISRS clinical practice recommendations for re-irradiation of spinal metastases with Stereotactic Body Radiotherapy: Delphi consensus supported by a systematic review and meta-analysis.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2026 Vol.214() p. 111304

Alongi F, Cuccia F, Kotecha R, Campione M, Louie AV, Ma L, Minniti G, Tree AC, Dahele M, Lo S, Af Rosenschold PM, Suh JH, Niyazi M, Sheehan J, Guckenberger M, Sahgal A

📝 환자 설명용 한 줄

[BACKGROUND] Stereotactic body radiotherapy (SBRT) is an established treatment for previously unirradiated spinal metastases; however, the literature is limited with respect to SBRT as a re-irradiatio

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 77-86
  • 추적기간 12 months
  • 연구 설계 systematic review

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Alongi F, Cuccia F, et al. (2026). ESTRO-ISRS clinical practice recommendations for re-irradiation of spinal metastases with Stereotactic Body Radiotherapy: Delphi consensus supported by a systematic review and meta-analysis.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 214, 111304. https://doi.org/10.1016/j.radonc.2025.111304
MLA Alongi F, et al.. "ESTRO-ISRS clinical practice recommendations for re-irradiation of spinal metastases with Stereotactic Body Radiotherapy: Delphi consensus supported by a systematic review and meta-analysis.." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol. 214, 2026, pp. 111304.
PMID 41344516

Abstract

[BACKGROUND] Stereotactic body radiotherapy (SBRT) is an established treatment for previously unirradiated spinal metastases; however, the literature is limited with respect to SBRT as a re-irradiation salvage therapy. We performed a systematic review and meta-analysis as basis for joint ESTRO-ISRS clinical practice recommendations of salvage SBRT for spinal metastases.

[METHODS] A systematic review and meta-analysis were performed using PRISMA methodology, including publications from January 2006 to September 2024, reporting on the clinical outcomes of ≥ 5 patients treated with spine SBRT re-irradiation (≥5 Gy per fraction) for vertebral metastases. These data served as basis for joint ESTRO-ISRS clinical practice recommendations.

[RESULTS] After the initial article screen, 20 studies (5 prospective, 15 retrospective) met the inclusion criteria for analysis. A total of 1538 spine metastases were treated in 1284 patients. The median re-irradiation dose was 24 Gy in 2 fractions (range: 16-30 Gy in 1-5 fractions) after a median 30 Gy in 10 fractions of prior conventional radiotherapy. Vertebral compression fracture, nerve root damage, and myelopathy events were observed in a pooled proportion of 5.0 %, 5.6 %, and 1.7 %, respectively. With a median follow-up of 12 months, the pooled 1- and 2-year LC rates were 81 % (95 % CI: 77-86 %) and 70 % (95 % CI: 61-79 %), respectively. Despite the low level of evidence, a consensus was reached after the first round of voting for 11 practice recommendations, suggesting a substantial level of agreement among the experts.

[CONCLUSIONS] Re-irradiation with SBRT for spine metastases following prior conventional radiation or SBRT was efficacious, safe, and is a recommended treatment option in appropriately selected patients. Joint practice recommendations are provided on behalf of ESTRO and ISRS to guide clinical practice.

MeSH Terms

Humans; Spinal Neoplasms; Radiosurgery; Re-Irradiation; Delphi Technique; Salvage Therapy

같은 제1저자의 인용 많은 논문 (1)